Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Blood Endocan as a Biomarker for Breast Cancer Recurrence

Kentaro Daiki
ORCID logo ,
Yoko Kanada
,
Aya Nagata
,
Kanae Taruno
ORCID logo ,
Katsuhide Igarashi
,
Toshiko Yamochi
,
Hirotaka Ota
,
Fumiaki Sato
,
Seigo Nakamura
* ,
Yoshinori Kato
* ORCID logo
Version 1 : Received: 11 January 2024 / Approved: 11 January 2024 / Online: 11 January 2024 (11:18:32 CET)

How to cite: Daiki, K.; Kanada, Y.; Nagata, A.; Taruno, K.; Igarashi, K.; Yamochi, T.; Ota, H.; Sato, F.; Nakamura, S.; Kato, Y. Blood Endocan as a Biomarker for Breast Cancer Recurrence. Preprints 2024, 2024010916. https://doi.org/10.20944/preprints202401.0916.v1 Daiki, K.; Kanada, Y.; Nagata, A.; Taruno, K.; Igarashi, K.; Yamochi, T.; Ota, H.; Sato, F.; Nakamura, S.; Kato, Y. Blood Endocan as a Biomarker for Breast Cancer Recurrence. Preprints 2024, 2024010916. https://doi.org/10.20944/preprints202401.0916.v1

Abstract

Blood-based biomarkers for early detection of recurrence have a significant clinical impact on the improved management of breast cancer patients, as cancer recurrence results in poor prognosis. This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers. Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3). Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan. Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.

Keywords

endocan; recurrence; biomarker; animal models; clinical study

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.